We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session
Opko Health, Inc. (OPK - Free Report) was a big mover last session, as its shares rose almost 6% on the day. The upside was driven by the FDA approval of Rayaldee for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. This also led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company since Jun 2, as the stock is now down almost 8%.
Over the last 30 days, the company witnessed one positive and one negative estimate revision. Meanwhile, the Zacks Consensus Estimate moved higher, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Opko Health has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
OPKO HEALTH INC Price
OPKO HEALTH INC Price | OPKO HEALTH INC Quote
A better-ranked stock in the med instruments space is CryoLife Inc. , sporting a Zacks Rank #1 (Strong Buy).
Is OPK going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>